批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2024/07/18 |
SUPPL-24(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2022/12/22 |
SUPPL-23(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2016/05/13 |
SUPPL-21(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2015/09/18 |
SUPPL-20(补充) |
Approval |
Labeling |
901 REQUIRED
|
|
|
2013/11/21 |
SUPPL-16(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
2008/12/17 |
SUPPL-14(补充) |
Approval |
Manufacturing (CMC) |
N/A
|
|
|
2004/01/21 |
SUPPL-10(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
1989/07/28 |
SUPPL-8(补充) |
Approval |
Labeling |
|
|
|
1987/05/14 |
SUPPL-7(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
1987/02/24 |
SUPPL-6(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
1984/12/04 |
SUPPL-5(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
1982/12/14 |
SUPPL-4(补充) |
Approval |
Labeling |
|
|
|
1981/06/23 |
SUPPL-3(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
1980/07/09 |
SUPPL-2(补充) |
Approval |
Manufacturing (CMC) |
PRIORITY
|
|
|
1979/09/07 |
SUPPL-1(补充) |
Approval |
Labeling |
|
|
|
1976/05/28 |
ORIG-1(原始申请) |
Approval |
Type 3 - New Dosage Form |
PRIORITY
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号 | 专利号 | 专利过期日 | 是否物质专利 | 是否产品专利 | 专利用途代码 | 撤销请求 | 提交日期 | 专利下载 | 备注 |
无 |
与本品治疗等效的药品
活性成分:DIAZOXIDE 剂型/给药途径:SUSPENSION;ORAL 规格:50MG/ML 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
017453 |
001 |
NDA |
PROGLYCEM |
DIAZOXIDE |
SUSPENSION;ORAL |
50MG/ML |
Prescription |
Yes |
Yes |
AB |
Approved Prior to Jan 1, 1982
|
TEVA BRANDED PHARM |
211050 |
001 |
ANDA |
DIAZOXIDE |
DIAZOXIDE |
SUSPENSION;ORAL |
50MG/ML |
Prescription |
No |
No |
AB |
2019/12/20
|
E5 PHARMA INC |
210799 |
001 |
ANDA |
DIAZOXIDE |
DIAZOXIDE |
SUSPENSION;ORAL |
50MG/ML |
Prescription |
No |
No |
AB |
2020/07/08
|
NOVITIUM PHARMA |